• Over 25 years of experience in the pharmaceutical industry
  • Former President, CEO and a Director of Mind Medicine Inc. (NEO:MMED), a pioneer in psychedelic drug development, for four months, prior to Mind Medicine becoming the  first psychedelics company to list on a stock exchange. 
  • For over two years was President & CEO of Cipher Pharmaceuticals Inc. (TSX:CPH), under his leadership the company was restored to positive EBITDA with the execution of 7 business development transactions to rapidly expand the product pipeline.
  • At Watson Pharmaceuticals, led the integration of major M&A transactions including Warner Chilcott (~$5B global acquisition), Forest Laboratories (~$28B global acquisition) and Allergan (~$66B global acquisition).
  • Commercial Development experience across numerous therapeutic areas including obesity, addiction, and neurologic disorders.